60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for malaria prevention among international travelers. ARAKODA is described as the only FDA-approved, broad-spectrum, once-weekly prescription malaria prevention on the U.S. market. Runway Health will offer physician-led online consultations and, if prescribed, seamless home delivery that arrives before departure. The partnership commences April 2, 2026 and lets eligible users match travel itineraries with personalized treatment plans designed by a U.S.-licensed healthcare provider.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.